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NMDA-type glutamate receptors are ligand-gated ion channels that
contribute to excitatory neurotransmission in the central nervous
system (CNS). Most NMDA receptors comprise two glycine-binding
GluN1 and two glutamate-binding GluN2 subunits (GluN2A–D). We
describe highly potent (S)-5-[(R)-2-amino-2-carboxyethyl]-4,5-dihy-
dro-1H-pyrazole-3-carboxylic acid (ACEPC) competitive GluN2 antag-
onists, of which ST3 has a binding affinity of 52 nM at GluN1/2A and
782 nM at GluN1/2B receptors. This 15-fold preference of ST3 for
GluN1/2A over GluN1/2B is improved compared with NVP-AAM077,
a widely used GluN2A-selective antagonist, which we show has 11-
fold preference for GluN1/2A over GluN1/2B. Crystal structures of
the GluN1/2A agonist binding domain (ABD) heterodimer with
bound ACEPC antagonists reveal a binding mode in which the li-
gands occupy a cavity that extends toward the subunit interface
between GluN1 and GluN2A ABDs. Mutational analyses show that
the GluN2A preference of ST3 is primarily mediated by four non-
conserved residues that are not directly contacting the ligand, but
positioned within 12 Å of the glutamate binding site. Two of these
residues influence the cavity occupied by ST3 in a manner that re-
sults in favorable binding to GluN2A, but occludes binding to
GluN2B. Thus, we reveal opportunities for the design of subunit-
selective competitive NMDA receptor antagonists by identifying a
cavity for ligand binding in which variations exist between GluN2A
and GluN2B subunits. This structural insight suggests that subunit
selectivity of glutamate-site antagonists can be mediated by mech-
anisms in addition to direct contributions of contact residues to
binding affinity.
synaptic transmission | Schild analysis | kinetic modeling |
X-ray crystallography | PEAQX
Glutamate mediates fast excitatory neurotransmission in themammalian CNS by binding to AMPA, kainate, and NMDA
receptors, which are ligand-gated ion channels involved in criti-
cal processes ranging from neuronal development to learning
and memory (1, 2). In particular, dysfunction or dysregulation of
NMDA receptors has been implicated in numerous neurological
and psychiatric disorders (1, 2). NMDA receptors are hetero-
tetrameric subunit assemblies containing two GluN1 subunits
that bind glycine or D-serine and two GluN2 subunits that bind
glutamate (3, 4). Four different GluN2 subunits (GluN2A–D)
exist that have distinct regional and developmental expression
patterns and endow NMDA receptor subtypes with strikingly
different biophysical and pharmacological properties (5, 6). The
GluN2 subunits therefore determine the physiological roles of
NMDA receptor subtypes, and, for this reason, they have re-
ceived considerable interest as potential therapeutic targets. To
this end, ligands that distinguish NMDA receptor subtypes based
on GluN2 subunits are desirable due to their obvious utility as
pharmacological tools and as potential therapeutic agents for the
treatment of CNS disorders (7, 8).
Considerable progress has been made in the development of
subunit-selective allosteric modulators (7–13), but the development
of subtype-selective competitive NMDA receptor antagonists has
been less successful. The competitive glutamate-site antagonist
NVP-AAM077 (hereafter NVP) was originally reported to have
100-fold preference for GluN1/2A over GluN1/2B (14). As such,
this compound has been extensively used to investigate the role of
GluN2A-containing receptors in different brain regions and cel-
lular processes. Subsequent studies using Schild analysis suggested
that NVP only has a 5.4-fold preference for GluN1/2A over
GluN1/2B (15). The modest 5.4-fold GluN2A preference of NVP
has not discouraged its use in numerous published studies as a
pharmacological tool compound to dissect the relative contribu-
tions of GluN2A- and GluN2B-containing NMDA receptors to
synaptic responses. The widespread use of competitive antagonists
with only modest subunit preference as tool compounds highlights
a broad interest in GluN2A-selective antagonists and suggests a
lack of structural and pharmacological understanding of competi-
tive antagonism at the glutamate site in NMDA receptors. Until
this study, crystal structures of NMDA receptor agonist binding
domains (ABDs) in complex with competitive antagonists have
been limited to the glycine site ligands—DCKA, cycloleucine, and
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TK40 (16-20) —and the glutamate site ligands—2-amino-5-
phosphonopentanoic acid (D-AP5), (−)-PPDA, and NVP (18, 21).
In this study, we explore the structural and pharmacological
properties of a series of ligands based on (S)-5-[(R)-2-amino-2-
carboxyethyl]-4,5-dihydro-1H-pyrazole-3-carboxylic acid (ACEPC)
(22). Competitive NMDA receptor antagonists in this series have
been evaluated as potential neuroprotective and radioligand imag-
ing agents (22, 23). Furthermore, preliminary functional results
suggested that addition of halogen substituents to one of these li-
gands, FRA-19 {(S)-5-[(R)-2-amino-2-carboxyethyl]-1-phenyl-4,5-
dihydro-1H-pyrazole-3-carboxylic acid}, resulted in modest pref-
erence for GluN1/2A over GluN1/2B receptors, as seen for
compounds ST1 {(S)-5-[(R)-2-amino-2-carboxyethyl]-1-(4-fluo-
rophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid} and ST6
{(S)-5-[(R)-2-amino-2-carboxyethyl)-1-(4-bromophenyl)-4,5-dihy-
dro-1H-pyrazole-3-carboxylic acid} (23). The GluN2A preference
prompted the synthesis of additional analogs, and we show here
that a compound in the ACEPC series of competitive antagonists, ST3
{(S)-5-[(R)-2-amino-2-carboxyethyl]-1-[4-(3-fluoropropyl)phenyl]-
4,5-dihydro-1H-pyrazole-3-carboxylic acid}, has a 15-fold prefer-
ence for GluN1/2A over GluN1/2B. To facilitate the design of
novel competitive antagonists, we use a combination of pharma-
cological, crystallographic, and mutational experiments to describe
the structural determinants of binding and subunit selectivity for
the ACEPC ligands.
Results
Pharmacology of ACEPC Compounds at NMDA Receptors. We per-
formed Schild analyses to determine binding affinities for the
ACEPC ligands at GluN1/2A and GluN1/2B receptors (Materials
and Methods). Schild analyses of glutamate concentration–response
relationships in the absence and presence of FRA-19, ST1, ST6,
or ST3 revealed variation in selectivity between GluN1/2A and
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Fig. 1. Schild analysis of NMDA receptor inhibition by competitive antagonists. (A–D) Glutamate concentration–response data in the absence and presence
of FRA-19 (A), ST1 (B), ST6 (C), or ST3 (D) and corresponding Schild plots for GluN1/2A and GluN1/2B determined using two-electrode voltage-clamp re-
cordings. Glutamate concentration–response data in the absence and presence of antagonist are analyzed using global nonlinear regression to determine
inhibition binding affinity (Ki). The dose ratio (DR) is the ratio of glutamate EC50 values in the presence and absence of antagonist. See SI Materials and
Methods for details and Table 1 for values. (E) Representative two-electrode voltage-clamp recordings of responses from GluN1/2A and GluN1/2B in the
absence and presence of ST3. [Scale bars: 200 nA (vertical) and 1 min (horizontal).]
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GluN1/2B depending on the substituents on the ligand phenyl ring.
FRA-19 (phenyl-ACEPC) displayed 4.0-fold preference for GluN1/2A
over GluN1/2B with binding affinities of 23 and 93 nM, respectively
(Fig. 1A and Table 1). ST1 (4-bromophenyl-ACEPC) and ST6
(4-fluorophenyl-ACEPC) displayed 4.6-fold (24 vs. 111 nM) and
8.5-fold (32 vs. 271 nM) preference for GluN1/2A over GluN1/2B
receptors, respectively (Fig. 1 B and C and Table 1). Most notably,
ST3 [4-(3-fluoropropyl)phenyl-ACEPC] was 15-fold selective for
GluN1/2A over GluN1/2B receptors (52 vs. 782 nM) (Fig. 1 D and
E and Table 1). To further evaluate the subunit selectivity of ST3,
we also determined binding affinities at GluN1/2C and GluN1/2D
using Schild analyses. The binding affinity of ST3 was 107
and 400 nM at GluN1/2C and GluN1/2D, respectively (Fig. S1).
ST3 therefore displays a marked preference for the glutamate
binding sites in GluN2A/C over GluN2B/D subunits. The Ki values
determined using Schild analyses are generally consistent with
corresponding Ki values estimated using the Cheng–Prusoff re-
lationship (Fig. S2 and Table S1). However, some differences are
expected due to limitations of the Cheng–Prusoff relationship (24),
highlighting the requirement of Schild analysis for more robust
determination of binding affinities (25). Thus, we demonstrate that
ST3 is a competitive antagonist with 15-fold preference for the
glutamate binding site in GluN2A over that in GluN2B.
Binding Affinities of D-AP5 and NVP at GluN1/2A and GluN1/2B. To
compare binding affinities of ACEPC ligands to well-known com-
petitive NMDA receptor antagonists, we evaluated the pharma-
cology of D-AP5 and NVP (Fig. 2). D-AP5 is commonly applied for
inhibition of neuronal NMDA receptors without consideration of
selectivity among receptor subtypes (i.e., D-AP5 is considered a
nonselective NMDA receptor antagonist) (26). Using Schild analysis,
we found that D-AP5 has a relatively low binding affinity compared
with the ACEPC ligands and displayed 5.9-fold preference for
GluN1/2A over GluN1/2B (Fig. 2A and Table 1). NVP has been
used in numerous studies as a GluN2A-selective antagonist to dif-
ferentiate the roles of GluN2A- and GluN2B-containing NMDA
receptors in synaptic transmission. Using Schild analysis, we de-
termined Ki values for NVP of 30 nM at GluN1/2A and 320 nM at
GluN1/2B, corresponding to 11-fold preference for GluN1/2A over
GluN1/2B (Fig. 2 B and C and Table 1). The original report eval-
uated NVP at human GluN1/2A and human GluN1/2B (14), and
discrepancies among studies regarding the subunit selectivity of NVP
could be attributed to differences between human and rat NMDA
receptors. Here, we determined 9.5-fold preference for human
GluN1/2A over human GluN1/2B, with Ki values of 20 and 186 nM,
respectively (Fig. S3 and Table 1). Thus, NVP binding is not no-
ticeably different between rat and human NMDA receptors. The
ACEPC ligands bind GluN1/2A with higher affinity (23–52 nM)
compared with the nonselective antagonist D-AP5 (282 nM at
GluN1/2A), and the 15-fold preference of ST3 for GluN1/2A over
GluN1/2B is modestly improved compared with NVP.
NMDA Receptor Inhibition Under Nonequilibrium Conditions. During
excitatory synaptic transmission, NMDA receptors are activated
by exposure to a high peak concentration of glutamate (∼1 mM)
for a few milliseconds (27). The presence of competitive antag-
onist will reduce the fraction of NMDA receptors that activate
during synaptic release of glutamate. That is, the antagonist will
bind a subset of NMDA receptors, depending on antagonist
concentration and binding affinity, and prevent agonist binding
and subsequent gating of these receptors after synaptic release
of glutamate; the mean lifetimes of antagonist–receptor com-
plexes are typically much longer than the few milliseconds that
glutamate is available for binding (28, 29). Frizelle et al. (15)
used kinetic modeling to predict that, under nonequilibrium
conditions relevant to those encountered during rapid release and
removal of synaptic glutamate, NVP is incapable of fully inhibiting
Table 1. Schild analysis of NMDA receptor inhibition by
competitive antagonists
Antagonist
GluN1/2A GluN1/2B
Ki, nM (95% CI) n Ki, nM (95% CI) n
FRA-19 22.6 (21.2–24.0) 39 93.3 (87.2–100) 38
ST1 24.3 (22.6–26.1) 24 111 (104–119) 33
ST6 32.2 (29.9–34.6) 35 271 (245–299) 34
ST3 51.8 (49.0–54.7) 30 782 (730–837) 24
D-AP5 282 (257–309) 25 1,670 (1,520–1,830) 26
NVP (rat) 29.7 (27.4–32.2) 47 320 (282–363) 34
NVP (human) 19.6 (17.9–21.3) 32 186 (168–207) 28
Glutamate concentration–response data in the absence or presence of
antagonist were analyzed by simultaneously fitting all data to both the
Schild and Hill equations using global nonlinear regression (SI Materials
and Methods). This analysis yields values for glutamate EC50 (in the absence
of antagonist) and antagonist binding affinity (Ki) that best describe all of
the experimental data. Ki values are listed with their 95% CI from the global
nonlinear least-squares fits. n is the total number of oocytes used to gener-
ate all glutamate concentration–response data in the absence or presence of
antagonist.
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Fig. 2. Schild analysis of NMDA receptor inhibition by D-AP5 and NVP. Glutamate concentration–response data in the absence and presence of D-AP5 (A) and
NVP (B) and corresponding Schild plots for GluN1/2A and GluN1/2B determined using two-electrode voltage-clamp recordings. See Table 1 for values.
E6944 | www.pnas.org/cgi/doi/10.1073/pnas.1707752114 Lind et al.
GluN1/2A without markedly reducing GluN1/2B responses. We
modeled inhibition of GluN1/2A and GluN1/2B by ST3 under
the same nonequilibrium conditions using a published kinetic
scheme (30). In this kinetic scheme (Fig. 3A; see Table S2 for
rate constants), the receptor contains two equivalent glutamate
binding sites (i.e., GluN2 subunits) and requires agonist occu-
pancy at both of these sites for activation. We assume that the
association rate (k+B) of the antagonist ST3 is 10 μM−1·s−1,
consistent with values for other competitive NMDA receptor
antagonists (28, 29). The antagonist dissociation rates (k-B) for
ST3 are therefore 0.52 s−1 at GluN1/2A and 7.8 s−1 at GluN1/2B, ac-
cording to the experimentally determined Ki values (Ki = k-B/k+B).
Using these parameters, we modeled inhibition of GluN1/2A and
GluN1/2B by ST3 for responses activated by exposure to 1 mM
glutamate for a duration of 1 ms (Fig. 3B). This modeling sug-
gests that 300 nM ST3 fully blocks peak responses from GluN1/
2A, but also inhibits peak responses from GluN1/2B by 48%.
Simulated concentration–response data under these nonequi-
librium conditions predict that, despite the 15-fold preference of
ST3 for GluN1/2A over GluN1/2B, it is not possible to achieve
full block of GluN1/2A without accompanying inhibition of
GluN1/2B responses (Fig. 3C).
To provide experimental data to support the simulations, we
used fast-application whole-cell patch-clamp recordings of re-
sponses from recombinant GluN1/2A, GluN1/2B, and trihe-
teromeric GluN1/2A/2B receptors expressed in HEK-293 cells.
We measured responses to a brief 1- to 3-ms exposure to 1 mM
glutamate in the continuous presence of 100 μM glycine and in
the absence or presence of 100 nM ST3 (Fig. 3D). Under these
conditions, the presence of ST3 inhibited peak responses from
GluN1/2A and triheteromeric GluN1/2A/2B by 76 ± 1% (n = 5)
and 62 ± 4% (n = 5), respectively, whereas peak responses from
GluN1/2B were reduced by 13 ± 4% (n = 6) (Fig. 3E). These
results are consistent with the simulated data and demon-
strate that 100 nM ST3 blocks a significant portion of responses
from GluN2A-containing NMDA receptors, but also produces
some inhibition of GluN1/2B responses. In theory, competitive
antagonists with >100-fold selectivity are required to produce
full inhibition of GluN1/2A without affecting GluN1/2B re-
ceptors under the conditions simulated here (Fig. 3C). How-
ever, a competitive antagonist with 100-fold selectivity for
GluN1/2A over GluN1/2B is still expected to produce robust
inhibition of triheteromeric GluN1/2A/2B receptors, which are
the primary GluN2B-containing NMDA receptors in the adult
hippocampus and cortex (31–33).
Crystal Structures of the GluN1/2A ABD Heterodimer in Complex with
ACEPC Ligands. To define the structural basis for selectivity of the
ACEPC compounds, we determined crystal structures of GluN1/
2A ABD heterodimers in complex with glycine and FRA-19
(2.4 Å), ST1 (2.11 Å), ST6 (2.3 Å), and ST3 (1.95 Å) (Fig. 4 and
Table S3). In these structures, the ACEPC ligands occupy the
glutamate binding site and stabilize a more open conformation
of the GluN2A ABD compared with agonists, consistent with
their mechanism of action as competitive antagonists (Fig. 4B)
(18). The degree of GluN2A ABD opening by the ACEPC li-
gands is similar to published GluN1/2A ABD heterodimer
structures in complex with the antagonists D-AP5, (−)-PPDA,
and NVP (18, 21), albeit (−)-PPDA stabilizes the GluN2A ABD
in a slightly more open conformation compared with the other
ligands. The degree of GluN2A ABD opening compared with
the glutamate-bound structure is ∼16° for D-AP5, ∼20° for
(−)-PPDA, ∼16° for NVP, ∼14° for ST1, ∼13° for ST3, ∼13° for
ST6, and ∼14° for FRA-19 (Materials and Methods). Polar in-
teractions between the ligand amino acid moiety and residues
in the upper lobe of the GluN2A ABD (D1) are conserved
among ACEPC compounds and D-AP5, but polar interactions
between ligands and residues in the lower lobe of the GluN2A
ABD (D2) are different for ACEPC ligands and D-AP5 (Fig. 4)
(18). Polar interactions are formed between the pyrazoline
2-nitrogen atoms of the ACEPC ligands and the side-chain hy-
droxyl of GluN2A Thr-690, whereas the distal carboxyl groups of
the ACEPC ligands interact with the backbone NH of GluN2A
Thr-690.
The published structure of the GluN1/2A ABD heterodimer in
complex with glycine and (‒)-PPDA revealed a binding mode in
which the phenanthrene group of (‒)-PPDA is oriented along
the cleft between the upper and lower lobes of the GluN2A ABD
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Fig. 3. Competitive antagonism under nonequilibrium conditions. (A) Kinetic scheme used to simulate NMDA receptor-mediated responses. The kinetic
scheme and rate constants are published (30). See Table S2 for rate constants. (B) Simulated responses mediated by GluN1/2A and GluN1/2B receptors to a
1-ms exposure to 1 mM glutamate in the absence (control) or continuous presence of increasing concentrations of ST3. EPSC, excitatory postsynaptic current.
(C) Simulated concentration–response data for inhibition of peak responses by ST3. The theoretical concentration–response data for a compound that inhibits
with 100-fold selectivity is shown for comparison. (D) Representative whole-cell voltage-clamp recordings of responses from recombinant GluN1/2A, trihe-
teromeric GluN1/2A/2B, and GluN1/2B receptors expressed in HEK-293 cells. Responses were activated by fast-application (1–3 ms) of 1 mM glutamate in the
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and forms a hydrophobic contact with the nonconserved residue
GluN2A Lys-738 (Fig. S4) (18). Interestingly, the ACEPC li-
gands adopt a strikingly different binding mode compared with
(‒)-PPDA, with the phenyl group and its substituents directed
into a cavity of the glutamate binding site toward the subunit
interface between GluN1 and GluN2A ABDs (Fig. 4; see also
Fig. S4 for additional justification of the binding pose). Recently,
the 4-bromophenyl substituent of NVP was shown to occupy the
same cavity in the GluN2A ABD (21), albeit the lack of an
amino acid moiety in NVP (Fig. 2B) results in a distinct binding
mode for this ligand compared with D-AP5, (‒)-PPDA, and
ACEPC ligands.
The cavity occupied by the substituted phenyl groups of the
ACEPC ligands extends from the central glutamate binding site
in GluN2A through an opening between the backbone and side
chain of Ser-689, the side chains of Thr-513 and Ile-533, and Gly-
532. The cavity is then lined by the side chains of Asn-693 and
Ile-533 at the bottom and by the side chains of Thr-513, Asn-515,
and Thr-759 at the top. The back wall of the cavity is lined by
Ala-757 from GluN2A and the side chain of GluN1 Glu-781. The
cavity is solvent-exposed through an opening between side chains
of GluN1 Glu-781 and GluN2A Asn-515, -693, and Ser-689. The
ACEPC ligands could be unambiguously fitted to their electron
densities and are not forming obvious polar contacts in this cavity
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Fig. 4. Structures of antagonist-bound GluN1/2A ABD heterodimers. (A) Structure of the NMDA receptor composed of two GluN1 and two GluN2 subunits
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ACEPC ligands in the open ABD conformation and extends from the glutamate binding site toward the ABD dimer interface. The cavity was detected using
CAVER (SI Materials and Methods). (D–G) Views of glutamate binding sites in GluN1/2A ABD heterodimer structures with bound FRA-19 (2.4 Å; D), ST1
(2.11 Å; E), ST6 (2.3 Å; F), and ST3 (1.95 Å; G). Select residues (gray carbon) within 4 Å of the ST3 ligand and potential polar interactions (dashed lines) are
shown. Residue GluN2A H485 and backbone atoms for some residues are omitted for clarity. The antagonists could be unambiguously fitted to their
electron densities shown as gray mesh (mFo − DFc omit map contoured at 3.0 σ; see Fig. S5 for contour level at 5.0 σ). See Table S3 for data collection and
refinement statistics.
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(Fig. 4; see also Fig. S5). The ACEPC ligands were refined with
an occupancy of 1.0, which yielded B factors for ligand atoms
that are similar surrounding protein atoms (see Table S3 for
average ligand B factors). The fluorine atom of ST3 is located
3.8 Å from the side chain carboxylate of GluN1 Glu-781 and
3.5 Å from the backbone carbonyl of GluN2A Ile-514. Thus, the
fluorine atom of ST3 could potentially form weak interactions
with either of these residues (34). This finding is similar to the
bromine atom of NVP in a recently described structure, in which
the bromine atom is located 3.5 Å from the side chain carbox-
ylate of GluN1 Glu-781 and could form a weak bromine–oxygen
interaction (21). In summary, all residues that line the binding
pocket for the ACEPC ligands, including the cavity occupied by
the substituted phenyl groups, are fully conserved among GluN2
subunits (Fig. S6), suggesting that the 15-fold GluN2A binding
preference of ST3 is not mediated by nonconserved residues in
direct contact with the ligand.
Identification of NMDA Receptor Regions That Mediate Subunit
Selectivity. The crystal structures provide insight to binding of
ACEPC ligands, but do not explicitly reveal the structural de-
terminants for the GluN2A preference of ST3. To identify re-
gions of GluN2A that mediate subunit selectivity of the ACEPC
compounds, we created chimeric GluN2 subunits by replacing
regions in GluN2A with corresponding regions from GluN2B
(Fig. 5A). First, the effects of swapping individual regions from
GluN2B into GluN2A on glutamate EC50 and ST3 IC50 were
evaluated using two-electrode voltage-clamp recordings (Fig. 5B
and Table S1). These values were then used to estimate the
ST3 binding affinity (Ki) using the Cheng–Prusoff relationship.
The amino-terminal domain (ATD) has a small, but significant,
influence on the GluN2A preference of ST3, because replacing
the GluN2A ATD with the GluN2B ATD reduced the estimated
ST3 binding affinity from 35 ± 1 nM (n = 42) at GluN1/2A to
60 ± 2 nM (n = 6) at GluN1/2A-(2B ATD) (Fig. 5 B–D and
Table S1). Swapping the GluN2B S1 segment, which forms ap-
proximately half of the ABD, into GluN2A did not change the
estimated binding affinity of ST3. By contrast, a strong effect was
observed with the introduction of the GluN2B S2 segment, which
forms roughly the other half of the ABD, into GluN2A. Schild
analysis determined Ki values of ST3 to be 687 nM [95% con-
fidence interval (CI) 612–772 nM, n = 23] and 588 nM (95% CI
504–686 nM, n = 20) at GluN1/2A-(2B S2) and GluN1/2A-(2B
S1+S2), respectively, which are markedly reduced compared
with GluN1/2A (52 nM) and more similar to the binding affinity
at GluN1/2B (782 nM) (Fig. 5E). These results demonstrate that
the S2 segment of the GluN2 ABD is the primary region in the
NMDA receptor that mediates the 15-fold preference of ST3 for
GluN1/2A over GluN1/2B.
Mutational Analysis of the GluN2A Preference for Competitive
Antagonists. We used site-directed mutagenesis to identify indi-
vidual residues that may contribute to the preference of ST3 for
GluN1/2A over GluN1/2B. We selected nonconserved residues
in GluN2A within 12 Å of ST3 in the crystal structure and
substituted these residues to the corresponding residues in
GluN2B (Fig. 6A and Fig. S6). The effects of substituting each of
these residues (GluN2A V529I, E714D, K738M, Y754K, I755V,
and T758S) on glutamate EC50 and ST3 IC50 were evaluated
using two-electrode voltage-clamp recordings (Fig. 6B and Table
S1). The V529I and Y754K substitutions had the greatest effect
on glutamate EC50: 4.2 and 1.3 μM, respectively, compared with
3.0 μM at wild-type GluN1/2A and 1.1 μM at GluN1/2B. We
then measured the IC50 of ST3 and used the Cheng–Prusoff
relationship to estimate Ki at each mutant receptor (Fig. 6B and
Table S1). Four of the individual mutations significantly in-
creased the estimated Ki of ST3 compared with GluN1/2A (35 ±
1 nM, n = 42) —namely, K738M (57 ± 1 nM, n = 13), Y754K
(86 ± 5 nM, n = 4), I755V (42 ± 1 nM, n = 8), and T758S (74 ±
1 nM, n = 6). To explore potential synergistic or additive effects
of these residues in mediating the GluN2A preference of ST3, we
performed mutant cycle analysis (35–37) by calculating coupling
coefficients for GluN2A K738M + Y754K (denoted K/M+Y/K),
K738M + T758S (K/M+T/S), and Y754K + T758S (Y/K+T/S)
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double substitutions (Fig. 6 C–E and Table S1). This mutant cycle
analysis compares the effects of mutation 1 when introduced
into receptors with mutation 2 or into wild-type receptors. A
coupling coefficient Ω of 1.0 indicates that mutation 1 has the
same effect in wild-type receptors as in the presence of muta-
tion 2 and that the two mutations are independent and additive
(i.e., energetically uncoupled; the coupling energy −RTlnΩ is
zero). Coupling coefficients Ω different from 1.0 indicate that
the effect of mutation 1 is modified by mutation 2 and that the
two mutations are nonadditive (i.e., energetically coupled). The
coupling coefficient of Ω = 1.01 for K/M+T/S suggests that the
effects of K738M and T758S mutations are additive and in-
dependent. Coupling coefficients of Ω = 0.86 and 0.70 for
K/M+Y/K and Y/K+T/S, respectively, suggest that the influ-
ence of K738M and T758S substitutions on ST3 binding affinity
is slightly modified by the Y754K substitution. More specifi-
cally, the Y754K substitution reduces the effects of the K738M
and T758S and vice versa. The Y754K substitution also in-
creases glutamate potency (Table S1), suggesting that this
mutation has a global effect on the GluN2A ABD, perhaps by
altering the dynamic behavior of the glutamate binding site. We
also evaluated the triple substitution GluN2A K738M + Y754K
+ T758S (K/M+Y/K+T/S) and the quadruple substitution K/M+
Y/K+I/V+T/S, which combines all four mutations with significant
effects on the estimated affinity of ST3. Estimation of ST3 binding
affinities for the triple and quadruple substitutions suggested that
the four residues mediate a majority, but not all, of the GluN2A
preference of ST3 (Fig. 6B and Table S1). We supported this
result using Schild analysis to determine the binding affinity of
ST3 at K/M+Y/K+I/V+T/S (435 nM, 95% CI 307–505 nM,
n = 29), which was markedly reduced compared with wild-type
GluN1/2A (52 nM) and closer to GluN1/2B (782 nM) (Fig. 6F
and Table 1).
To address whether the effects of the identified residues are
specific to ST3, we used Schild analysis to determine the binding
affinity of D-AP5 at wild-type GluN1/2A and GluN1/2B, as well
as K/M+Y/K+I/V+T/S. We found that the binding affinity of
D-AP5 was significantly reduced to 1.19 μM (95% CI 1.08–1.32 μM,
n = 31) by the quadruple substitution compared with 282 nM at
GluN1/2A and 1.67 μM at GluN1/2B (Fig. 7A and Table 1). To
identify the individual residues that affect D-AP5 binding, we
estimated the affinity of D-AP5 at each of the four single mutants
using the Cheng–Prusoff relationship (Fig. 7B and Table S1).
Two of these substitutions, K738M and Y754K, significantly
reduced the estimated binding affinity of D-AP5 compared with
wild-type GluN1/2A, whereas the other two substitutions, T758S
and I755V, had no effect on D-AP5 binding. To determine
whether the identified residues similarly affect NVP and ST3, we
used Schild analysis to determine the binding affinity of NVP at
wild-type GluN1/2A and GluN1/2B, as well as K/M+Y/K+I/V+
T/S. We found that the binding affinity of NVP was signifi-
cantly reduced to 193 μM (95% CI 174–215 nM, n = 31) by the
quadruple substitution compared with 30 nM at GluN1/2A and
320 μM at GluN1/2B (Fig. 7C and Table 1). Estimation of NVP
affinity using the Cheng–Prusoff relationship showed that three
of the substitutions, K738M, Y754K, and T758S, significantly
reduced the estimated binding affinity of NVP compared with
wild-type GluN1/2A, whereas I755V had no effect on NVP
binding (Fig. 7D and Table S1).
In summary, GluN2A Lys-738 and Tyr-754 residues appear to
have nonspecific effects on binding of competitive antagonists at
the glutamate binding site, whereas ST3 binding is also influenced
by GluN2A Ile-755 and Thr-758 residues. NVP binding is influ-
enced by GluN2A Thr-758, but not Ile-755, consistent with the
4-bromophenyl substituent of NVP occupying the same cavity as
the substituted phenyl group of ST3. These results also suggest
that the 11-fold preference of NVP for GluN2A over GluN2B is
mediated, in part, by indirect engagement of the 4-bromophenyl
substituent with the nonconserved GluN2A Thr-758 residue,
whereas the 15-fold GluN2A preference of ST3 is achieved by
engaging both GluN2A Ile-755 and Thr-758.
Discussion
In this study, we have provided structural and functional insight
into binding of ACEPC competitive antagonists at the NMDA
receptor glutamate binding site. The ACEPC ligands have a
binding mode in which they occupy an extension of the glutamate
binding site near the subunit interface between the GluN1 and
GluN2A ABDs. One of the compounds, ST3, which extends into
this cavity, has 15-fold preference for GluN1/2A over GluN1/2B.
We found that the GluN2A preference of ST3 was mediated by
the S2 region of the GluN2A ABD with four nonconserved
residues (GluN2A Lys-738, Tyr-754, Ile-755, and Thr-758) being
responsible for the majority of the difference in antagonist
binding between GluN2A and GluN2B subunits (Figs. 5 and 6).
Two of these residues, GluN2A Lys-738 and Tyr-754, did not
selectively influence ST3 binding, because they also shaped the
modest 5.9- and 11-fold preference of D-AP5 and NVP, re-
spectively, for GluN1/2A over GluN1/2B (Fig. 7). GluN2A Lys-
738 and Tyr-754 were previously found to play critical roles in
the binding preference of conantokin-G, a GluN1/2B-selective
peptide toxin (38). In addition, GluN2A Lys-738 was shown to
mediate the preferential binding of (‒)-PPDA to GluN1/2B-D
receptors, consistent with the distinct binding mode adopted by
this ligand and its direct contact with this residue (Fig. S4) (18).
GluN2A Lys-738 and Tyr-754 have also been shown to influence
glycine potency, albeit the mechanism by which these residues
affect agonist activity at the GluN1 subunit are unclear (39).
Finally, GluN2A Lys-738 influences inhibition by the GluN2D-
selective negative allosteric modulator, QNZ-46, which requires
glutamate binding for its activity (40). Thus, GluN2A Lys-
738 and Tyr-754 appear to have global effects on ligand binding
to the GluN2 ABD. We suggest that these residues may indi-
rectly affect binding of competitive antagonists by changing the
relative stabilities of open and closed conformations (i.e., the
dynamic behavior of the ABD) and/or by influencing the orien-
tation of the upper and lower lobes of the ABD. Given the lo-
cation of GluN2A Tyr-754 (Fig. 6A), it is possible that the
residue at this position is implicated in interactions between
GluN1 and GluN2A ABDs that change during transitions be-
tween open and closed ABD conformations (i.e., agonist- and
antagonist-bound conformations). GluN2A Lys-738 is positioned
to influence the hydrogen-bonding network surrounding the
glutamate binding site and could also affect cross-cleft interac-
tions between the upper and lower lobes of the GluN2A ABD
(Fig. 6A). In this way, GluN2A Lys-738 and Tyr-754 may
enhance antagonist binding in GluN2A compared with in
GluN2B-D, where these residues are methionine and lysine,
respectively. Nonetheless, the mechanisms by which GluN2A
Lys-738 and Tyr-754 influence ligand binding to the GluN2A
ABD remain elusive.
Conversely, GluN2A Ile-755 and Thr-758 specifically influence
ST3 binding and are located closer to the 4-(3-fluoropropyl)phenyl
group of ST3 compared with GluN2A Lys-738 and Tyr-754 (Fig.
6A). The side chains of GluN2A Ile-755 and Thr-758 are in close
proximity to each other as part of a larger hydrophobic cluster of
residues at the interface between GluN1 and GluN2A ABDs.
Small perturbations to the side chains of GluN2A Ile-755 and Thr-
758, as with I755V and T758S mutations, could alter the positions
of neighboring residues, three of which (GluN2A Gly-532, Ala-
757, and Thr-759) line the cavity occupied by the 4-(3-fluo-
ropropyl)phenyl group of ST3. We therefore suggest that GluN2A
Ile-755 and Thr-758 influence the shape and volume of the cavity
favorably for ST3 binding, whereas valine and serine residues at
these positions in GluN2B result in a less optimal cavity for
ST3 binding. This idea is supported by a recent structure of the
GluN1/2A ABD dimer in complex with NVP, which revealed that
the 4-bromophenyl group of NVP extends into the same cavity
as the substituted phenyl groups of the ACEPC ligands (21).
We show that binding affinities of NVP and ST1, which also has a
4-bromophenyl group, are very similar for the GluN2A ABD
(30 and 24 nM, respectively), but NVP has a lower affinity for the
GluN2B ABD compared with ST1 (320 and 111 nM, respectively)
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(Table 1). The 4-bromophenyl group of NVP is located deeper in
the cavity compared with the 4-bromophenyl group of ST1 (i.e.,
the distance between the bromine and the carboxylate of GluN1
Glu-781 is 3.5 Å for NVP and 6.7 Å for ST1). This finding dem-
onstrates that the same substituent (4-bromophenyl) positioned
differently in the cavity does not change affinity at GluN2A, but,
rather, reduces binding to GluN2B. Thus, the GluN2A preference
for the ACEPC ligands, and likely NVP, is not mediated by in-
creased binding to GluN2A, but, rather, occlusion of binding to
GluN2B. Because residues lining the cavity are conserved between
GluN2A and GluN2B, the occlusion from GluN2B binding is
presumably mediated by steric differences related to the shape
and/or volume of the cavity. In this regard, the relatively high
binding affinity of ST3 at GluN1/2C receptors (107 nM) is sur-
prising (Fig. S1), because sequence analysis suggests that ST3
binding to GluN2C should be similar to GluN2B and GluN2D
(Fig. S6). However, GluN1/2C receptors may have additional,
unique structural determinants that facilitate binding of ST3 and
other ligands at the glutamate site.
The 15-fold preference of ST3 for inhibition of GluN1/2A
over GluN1/2B receptors is improved compared with described
GluN2A-preferring competitive antagonists (15, 41–43). However,
our kinetic modeling and fast-application patch-clamp recordings
suggest that 15-fold subunit preference is not sufficient to fully
distinguish between GluN1/2A and GluN1/2B receptors under
conditions relevant to synaptic transmission (Fig. 3). This issue is
further complicated when triheteromeric GluN1/2A/2B receptors
are considered, because these receptors are inhibited by ST3 to a
similar level as GluN1/2A receptors (Fig. 3 D and E). NMDA re-
ceptors require simultaneous occupancy at both agonist binding
sites in the two GluN2 subunits for channel gating, and binding of
one competitive antagonist will therefore prevent activation (44).
Thus, competitive antagonists with high GluN2A selectivity would
result in full inhibition of GluN1/2A and GluN1/2A/2B receptors,
thereby enabling pharmacological isolation of GluN1/2B re-
ceptors. By contrast, some highly subunit-selective negative
allosteric modulators are less effective inhibitors of trihe-
teromeric GluN1/2A/2B receptors and therefore primarily inhibit
either GluN1/2A or GluN1/2B receptors [e.g., TCN-201 or ifen-
prodil, respectively (20, 45)]. Both subunit selectivity and mecha-
nism of action are therefore important considerations for the
application of a pharmacological tool compound in neurophysio-
logical studies, because many central synapses in the adult hippo-
campus and cortex contain a mixed population of GluN1/2A,
GluN1/2B, and triheteromeric GluN1/2A/2B receptors (31).
The development of highly subunit-selective competitive glutamate-
site antagonists that can distinguish between NMDA receptor sub-
types based on GluN2 subunits has so far been unsuccessful. The
insights into binding of ACEPC competitive antagonists revealed in
this study provide a starting point for manipulations of existing li-
gands and for additional medicinal chemistry. The structural insight
provided here is a prerequisite for rational drug design and suggests
that glutamate-site competitive antagonists with considerable subunit
selectivity can be developed, despite the highly conserved nature of
the glutamate binding site. This work, therefore, facilitates the de-
velopment of highly subunit-selective competitive NMDA receptor
antagonists, which are critical to advancing our understanding of
NMDA receptor subtypes in the CNS, as well as for the development
of new therapeutic agents.
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Fig. 6. Identification of nonconserved residues that mediate ST3 subunit
selectivity. (A) Structure of the GluN1/2A ABD heterodimer with bound ST3.
Residues that are nonconserved between GluN2A and GluN2B and within
12 Å of ST3 are shown as salmon carbon. (B) Bar graph of ST3 binding af-
finities (Ki) for wild-type and mutant NMDA receptors estimated using the
Cheng–Prusoff relationship. Mutations are made in GluN2A to the corre-
sponding residues in GluN2B (Fig. S6). Double (e.g., K/M+Y/K), triple (K/M+Y/
K+T/S), and quadruple (K/M+Y/K+I/V+T/S) substitutions are abbreviated.
*P < 0.05 (significantly different from GluN1/2A; one-way ANOVA with
Tukey–Kramer posttest). See Table S1 for values. (C–E) ST3 concentration–
inhibition data and mutant cycle analysis for wild-type, single-, and double-
mutant NMDA receptors. Coupling coefficients (Ω = Ki,WT × Ki,M1+M2/Ki,M1 ×
Ki,M2) were calculated using estimated binding affinities from Table S1.
(F) Glutamate concentration–response data in the absence and presence of
ST3 and corresponding Schild plot for GluN1/2A K/M+Y/K+I/V+T/S. Data for
wild-type GluN1/2A (black) and GluN1/2B (blue) are shown for comparison.
See also Table S1.
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Materials and Methods
DNA Constructs and Ligands. Rat cDNAs for GluN1-1a (GenBank accession no.
U08261; hereafter GluN1), GluN2A (D13211), GluN2B (U11419), GluN2C
(M91563), and GluN2D (L31611) were provided by S. Heinemann, Salk In-
stitute, La Jolla, CA; S. Nakanishi, Osaka Bioscience Institute, Osaka; and
P. Seeburg, University of Heidelberg, Heidelberg. DNA constructs for human
GluN1-1a, GluN2A, and GluN2B subunits have been described (46). DNA
constructs for expression of rat triheteromeric GluN1/2A/2B receptors have
also been described (45). Additional details on the DNA constructs and the
chimeric GluN2A-GluN2B subunits are described in SI Materials and Methods.
The amino acids are numbered according to the full-length protein,
including the signal peptide. See also SI Materials and Methods and Fig. S7
for details on ligands and synthesis of ST3.
Two-Electrode Voltage-Clamp Recordings. See SI Materials and Methods for
details on NMDA receptor expression in Xenopus oocytes. Electrophysio-
logical recordings were performed at room temperature (23 °C) as described
(47). The oocytes were voltage-clamped at −40 mV during recordings. The
extracellular recording solution contained (in mM) 90 NaCl, 1 KCl, 10 Hepes,
0.5 BaCl2, and 0.01 EDTA (pH 7.4 with NaOH), and recording electrodes were
filled with 3 M KCl. Approximately 10–30 min before recordings, oocytes
expressing GluN1/2A and GluN1/2B receptors were injected with 20–50 nL of
50 mM BAPTA to prevent activity-dependent increases in response ampli-
tude (48).
Whole-Cell Patch-Clamp Recordings. Cell culturing and expression of NMDA
receptors in HEK-293 cells are described in SI Materials and Methods. Re-
cordings were performed using an Axopatch 200B amplifier (Molecular
Devices) at room temperature (23 °C) with the holding potential at −60 mV.
Electrodes were filled with internal solution containing (in mM) 110 D-glu-
conate, 110 CsOH, 30 CsCl, 5 Hepes, 4 NaCl, 0.5 CaCl2, 2 MgCl2, 5 BAPTA,
2 NaATP, and 0.3 NaGTP (pH 7.35 with CsOH), and the extracellular re-
cording solution was composed of (in mM) 150 NaCl, 10 Hepes, 3 KCl, 0.5
CaCl2, 0.01 EDTA, and 20 mM D-mannitol (pH 7.4 with NaOH). The speed of
solution exchange was measured at 0.4–0.8 ms (10–90% rise times) from the
open tip junctional potential and was achieved using a two-barrel theta-
glass pipette controlled by a piezoelectric translator.
Kinetic Modeling of NMDA Receptor Current Responses. Simulations of GluN1/
2A and GluN1/2B synaptic currents were performed using Kinetic Model
Builder (Version 2.0) (49). Published kinetic schemes and rate constants for
activation of GluN1/2A and GluN1/2B (30) can be found in Table S2, along
with ST3 binding and unbinding rates. Synaptic-like NMDA receptor re-
sponses were simulated by an instantaneous step change from 0 to 1 mM
glutamate for a duration of 1 ms.
Data Analysis. See SI Materials and Methods for details on estimation of Ki
values using the Cheng–Prussoff relationship, Schild analysis, and mutant
cycle analysis.
Crystallography of GluN1 and GluN2A ABDs. Details on expression, purifica-
tion, and crystallization of GluN1 and GluN2A ABDs are described in SI
Materials and Methods. Diffraction data were collected at the Advanced
Photon Source SBC-CAT 19-ID beamline. Images were processed using
HKL2000 (50). The initial phasing maps were determined by molecular re-
placement in PHASER (51) using the published glycine/glutamate-bound
GluN1/2A ABD structure [PDB ID code 4NF8 (18)] as search model. The ini-
tial models of antagonist-bound structures were built into a 2mFo − DFc map
with COOT (52) and subjected to one cycle of rigid-body refinement using
PHENIX (53). ACEPC ligands were then located and fitted in a mFo − DFc omit
map for each structure (54). The models were then further refined by iter-
ative model rebuilding into a sigma-weighted 2jFoj − jFcj map in COOT and
refinement cycles in PHENIX. Data collection and refinement statistics are
shown in Table S3. The coordinates and structure factors have been de-
posited to the PDB with ID codes 5VIJ (ST1), 5VII (ST3), 5VIH (ST6), and 5DEX
(FRA-19). See SI Materials and Methods for details on calculation of the
degree of opening of the GluN2A ABD by the antagonists compared with
the glutamate-bound GluN1/2A ABD dimer structure and for details on
detection of the cavity extending from the glutamate binding site in GluN2A
toward the interface between GluN1 and GluN2A ABDs.
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